it means a number of sub groups hit it out of the ball park but for the whole trial it looks like there was a treatment effect size of 50% reduction in 20% more of the experimental patients than controls. as the primary was 50% more this has not met but I just don’t think it’s going to matter a jot at the end of the day. They were always going to do another trial with grun in Europe anyway and too much of this data is landmark that won’t be able to be ignored by the fda.
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-101
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
-0.035(3.52%) |
Mkt cap ! $1.124B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 95.0¢ | $1.467M | 1.505M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 114808 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 34020 | 38 |
View Market Depth
| Last trade - 13.40pm 20/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |